Inhibition of inflammation and fibrosis by a complement C5a receptor antagonist in DOCA-salt hypertensive rats

Journal of Cardiovascular Pharmacology

Volumn 58, Issue 5, 2011, Pages 479-486

  Iyer, Abishek ^a   Woodruff, Trent M ^a   Wu, Mike C L ^a   Stylianou, Con ^a   Reid, Robert C ^a   Fairlie, David P ^a   Taylor, Stephen M ^a   Brown, Lindsay ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SOUTHERN QUEENSLAND   (Australia)

Author keywords

C5aR; cardiovascular remodeling; complement; DOCA salt; fibrosis; inflammation

Indexed keywords

COLLAGEN; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT INHIBITOR; DEOXYCORTICOSTERONE ACETATE; PMX 53; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CARDIOVASCULAR FUNCTION; CARDITIS; CELL INFILTRATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; EXTRAVASATION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; INFLAMMATION; INFLAMMATORY CELL; LEUKOCYTE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; VENTRICULAR STIFFNESS;

ACETYLCHOLINE; ANIMALS; AORTA, THORACIC; BLOOD PRESSURE; CARDIAC OUTPUT; CICATRIX; COLLAGEN; CORONARY CIRCULATION; DESOXYCORTICOSTERONE; ECHOCARDIOGRAPHY; ENDOMYOCARDIAL FIBROSIS; GENE EXPRESSION; HEART; HEART VENTRICLES; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INFLAMMATION; LEUKOCYTES, MONONUCLEAR; MALE; MAST CELLS; MYOCARDIUM; NITROPRUSSIDE; NOREPINEPHRINE; PEPTIDES, CYCLIC; RATS; RATS, WISTAR; RECEPTOR, ANAPHYLATOXIN C5A; VASOCONSTRICTION; VASODILATION; VENTRICULAR DYSFUNCTION;

EID: 80955158802     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31822a7a09     Document Type: Article

References (55)

1. Rutschow S, Li J, Schultheiss HP, et al. Myocardial proteases and matrix remodelling in inflammatory heart disease. Cardiovasc Res. 2006;69: 646-656.
2. Levick SP, Loch DC, Taylor SM, et al. Arachidonic acid metabolism as a potential mediator of cardiac fibrosis associated with inflammation. J Immunol. 2007;178:641-646.
3. Levick S, Loch D, Rolfe B, et al. Antifibrotic activity of an inhibitor of group IIA secretory phospholipase A2 in young spontaneously hypertensive rats. J Immunol. 2006;176:7000-7007.
4. Nicoletti A, Michel JB. Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovasc Res. 1999;41: 532-543.
5. Monk PN, Scola AM, Madala P, et al. Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol. 2007;152: 429-448.
6. Morgan BP. Complement regulatory molecules: application to therapy and transplantation. Immunol Today. 1995;16:257-259.
7. Sjoberg A, Onnerfjord P, Morgelin M, et al. The extracellular matrix and inflammation: fibromodulin activates the classical pathway of complement by directly binding C1q. J Biol Chem. 2005;280:32301-32308.
8. Woodruff TM, Strachan AJ, Dryburgh N, et al. Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat. Arthritis Rheum. 2002;46:2476-2485.
9. Shin HS, Snyderman R, Friedman E, et al. Chemotactic and anaphylatoxic fragment cleaved from the fifth component of guinea pig complement. Science. 1968;162:361-363.
10. Manthey HD,Woodruff TM, Taylor SM, et al. Complement component 5a (C5a). Int J Biochem Cell Biol. 2009;41:2114-2117.
11. Amsterdam EA, Stahl GL, Pan HL, et al. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol. 1995;268:H448-H457.
12. Zhang H, Qin G, Liang G, et al. C5aR-mediated myocardial ischemia/ reperfusion injury. Biochem Biophys Res Commun. 2007;357:446-452.
13. Oksjoki R, Laine P, Helske S, et al. Receptors for the anaphylatoxins C3a and C5a are expressed in human atherosclerotic coronary plaques. Atherosclerosis. 2007;195:90-99.
14. Oksjoki R, Kovanen PT, Mayranpaa MI, et al. Complement regulation in human atherosclerotic coronary lesions. Immunohistochemical evidence that C4b-binding protein negatively regulates the classical complement pathway, and that C5b-9 is formed via the alternative complement pathway. Atherosclerosis. 2007;192:40-48.
15. Kuwahara F, Kai H, Tokuda K, et al. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension. 2004;43:739-745.
16. Tomita H, Egashira K, Kubo-Inoue M, et al. Inhibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels. Arterioscler Thromb Vasc Biol. 1998; 18:1456-1464.
17. Koyanagi M, Egashira K, Kubo-Inoue M, et al. Role of transforming growth factor-beta1 in cardiovascular inflammatory changes induced by chronic inhibition of nitric oxide synthesis. Hypertension. 2000;35:86-90.
18. Yu Q, Watson RR, Marchalonis JJ, et al. A role for T lymphocytes in mediating cardiac diastolic function. Am J Physiol Heart Circ Physiol. 2005;289:H643-H651.
19. Yu Q, Horak K, Larson DF. Role of T lymphocytes in hypertensioninduced cardiac extracellular matrix remodeling. Hypertension. 2006;48: 98-104.
20. Levick SP, McLarty JL, Murray DB, et al. Cardiac mast cells mediate left ventricular fibrosis in the hypertensive rat heart. Hypertension. 2009;53: 1041-1047.
21. Fonseca MI, Ager RR, Chu SH, et al. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol. 2009;183:1375-1383.
22. Reid RC, Abbenante G, Taylor SM, et al. A convergent solution-phase synthesis of the macrocycle Ac-Phe-[Orn-Pro-D-Cha-Trp-Arg], a potent new antiinflammatory drug. J Org Chem. 2003;68:4464-4471.
23. Iyer A, Fenning A, Lim J, et al. Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. Br J Pharmacol. 2010;159:1408-1417.
24. Chan V, Hoey A, Brown L. Improved cardiovascular function with aminoguanidine in DOCA-salt hypertensive rats. Br J Pharmacol. 2006; 148:902-908.
25. Fenning A, Harrison G, Rose'meyer R, et al. L-Arginine attenuates cardiovascular impairment in DOCA-salt hypertensive rats. Am J Physiol. 2005;289:1408-1416.
26. Iyer A, Brown L. Fermented wheat germ extract (Avemar) in the treatment of cardiac remodeling and metabolic symptoms in rats. Evid Based Complement Altern Med. 2011; Article 508957: doi:10.1093/ecam/ nep090.
27. O'Brien D, Chunduri P, Iyer A, et al. L-Carnitine attenuates cardiac remodelling rather than vascular remodelling in deoxycorticosterone acetatesalt hypertensive rats. Basic Clin Pharmacol Toxicol. 2010;106:296-301.
28. Brown L, Fenning A, Chan V, et al. Echocardiographic assessment of cardiac structure and function in rats. Heart Lung Circ. 2002;11:167-173.
29. Litwin SE, Katz SE, Morgan JP, et al. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation. 1994;89:345-354.
30. Loch D, Hoey A, Morisseau C, et al. Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem Biophys. 2007;47:87-98.
31. Loch D, Levick S, Hoey A, et al. Rosuvastatin attenuates hypertensioninduced cardiovascular remodelling without affecting blood pressure in DOCA-salt hypertensive rats. J Cardiovasc Pharmacol. 2006;47: 396-404.
32. Proctor LM, Moore TA, Monk PN, et al. Complement factors C3a and C5a have distinct hemodynamic effects in the rat. Int Immunopharmacol. 2009;9:800-806.
33. Finch AM, Wong AK, Paczkowski NJ, et al. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J Med Chem. 1999;42:1965-1974.
34. Woodruff TM, Arumugam TV, Shiels IA, et al. A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J Immunol. 2003;171:5514-5520.
35. Woodruff TM, Arumugam TV, Shiels IA, et al. Protective effects of a potent C5a receptor antagonist on experimental acute limb ischemiareperfusion in rats. J Surg Res. 2004;116:81-90.
36. Woodruff TM, Crane JW, Proctor LM, et al. Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB J. 2006; 20:1407-1417.
37. Woodruff TM, Costantini KJ, Taylor SM, et al. Role of complement in motor neuron disease: animal models and therapeutic potential of complement inhibitors. Adv Exp Med Biol. 2008;632:143-158.
38. Woodruff TM, Costantini KJ, Crane JW, et al. The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J Immunol. 2008;181:8727-8734.
39. Ting E, Guerrero AT, Cunha TM, et al. Role of complement C5a in mechanical inflammatory hypernociception: potential use of C5a receptor antagonists to control inflammatory pain. Br J Pharmacol. 2008;153: 1043-1053.
40. Arumugam TV, Shiels IA, Woodruff TM, et al. Protective effect of a new C5a receptor antagonist against ischemia-reperfusion injury in the rat small intestine. J Surg Res. 2002;103:260-267.
41. Arumugam TV, Woodruff TM, Stocks SZ, et al. Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats. J Hepatol. 2004;40:934-941.
42. Arumugam TV, Shiels IA, Woodruff TM, et al. The role of the complement system in ischemia-reperfusion injury. Shock. 2004;21:401-409.
43. Manthey HD, Thomas AC, Shiels IA, et al. Complement C5a inhibition reduces atherosclerosis in ApoE-/- mice. FASEB J. 2011;25:2447-2455.
44. Kohl J. The role of complement in danger sensing and transmission. Immunol Res. 2006;34:157-176.
45. BjerreM, Hansen TK, Flyvbjerg A. Complement activation and cardiovascular disease. Horm Metab Res. 2008;40:626-634.
46. Kanzaki Y, Terasaki F, Okabe M, et al. Myocardial inflammatory cell infiltrates in cases of dilated cardiomyopathy as a determinant of outcome following partial left ventriculectomy. Jpn Circ J. 2001;65: 797-802.
47. Hinglais N, Huedes D, Nicoletti A, et al. Colocalization of myocardial fibrosis and inflammatory cells in rats. Lab Invest. 1994;70:286-294.
48. Brown D, Ambler SK, Mitchell MD, et al. The cardiac fibroblast: therapeutic target in myocardial remodelling and failure. Annu Rev Pharmacol Toxicol. 2005;45:657-687.
49. T Chakraborti, A Mandal, M Mandal, et al. Complement activation in heart diseases. Role of oxidants. Cell Signal. 2000;12:607-617.
50. Atefi G, Zetoune FS, Herron TJ, et al. Complement dependency of cardiomyocyte release of mediators during sepsis. FASEB J. 2011; 25:2500-2508.
51. Jalili A, Shirvaikar N, Marquez-Curtis L, et al. Fifth complement cascade protein (C5) cleavage fragments disrupt the SDF-1/CXCR4 axis: further evidence that innate immunity orchestrates the mobilization of hematopoietic stem/progenitor cells. Exp Hematol. 2010;38:321-332.
52. Willems IE, Havenith MG, De-Mey JG, et al. The alpha-smooth muscle actin-positive cells in healing human myocardial scars. Am J Pathol. 1994; 145:868-875.
53. Nakatsuji S, Yamate J, Kuwamura M, et al. In vivo responses of macrophages and myofibroblasts in the healing following isoproterenolinduced myocardial injury in rats. Virchows Arch. 1997;430:63-69.
54. Vyalov S, Desmouliere A, Gabbiani G. GM-CSF-induced granulation tissue formation: relationships between macrophage and myofibroblast accumulation. Virchows Arch. 1993;63:231-239.
55. Mirkovic S, Seymour AM, Fenning A, et al. Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. Br J Pharmacol. 2002;135:961-968.